Metabolic effects of diphosphonate in primary hyperparathyroidism

R. A. Kaplan, W. B. Geho, C. Poindexter, M. Haussler, G. W. Dietz, C. Y. Pak

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Six patients with primary hyperparathyroidism (PHPT) and one with squamous cell carcinoma of the esophagus with parathyroid hormone excess received disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) at a daily dose of 20 mg/kg orally. During treatment, the decrease in urinary calcium, total urinary hydroxyproline, and fasting urinary calcium suggested an inhibition of bone resorption. Serum calcium intestinal absorption of calcium and urinary cyclic adenosine monophosphate (cAMP) did not change significantly. This preliminary study indicates a possible role of diphosphonates in the management of inoperable cases of primary hyperparathyroidism or pseudohyperparathyroidism.

Original languageEnglish (US)
Pages (from-to)410-419
Number of pages10
JournalJournal of Clinical Pharmacology
Volume17
Issue number7
StatePublished - 1977

Fingerprint

Primary Hyperparathyroidism
Diphosphonates
Calcium
Ethane
Hydroxyproline
Intestinal Absorption
Case Management
Bone Resorption
Parathyroid Hormone
Cyclic AMP
Esophagus
Squamous Cell Carcinoma
Fasting
Serum
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kaplan, R. A., Geho, W. B., Poindexter, C., Haussler, M., Dietz, G. W., & Pak, C. Y. (1977). Metabolic effects of diphosphonate in primary hyperparathyroidism. Journal of Clinical Pharmacology, 17(7), 410-419.

Metabolic effects of diphosphonate in primary hyperparathyroidism. / Kaplan, R. A.; Geho, W. B.; Poindexter, C.; Haussler, M.; Dietz, G. W.; Pak, C. Y.

In: Journal of Clinical Pharmacology, Vol. 17, No. 7, 1977, p. 410-419.

Research output: Contribution to journalArticle

Kaplan, RA, Geho, WB, Poindexter, C, Haussler, M, Dietz, GW & Pak, CY 1977, 'Metabolic effects of diphosphonate in primary hyperparathyroidism', Journal of Clinical Pharmacology, vol. 17, no. 7, pp. 410-419.
Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CY. Metabolic effects of diphosphonate in primary hyperparathyroidism. Journal of Clinical Pharmacology. 1977;17(7):410-419.
Kaplan, R. A. ; Geho, W. B. ; Poindexter, C. ; Haussler, M. ; Dietz, G. W. ; Pak, C. Y. / Metabolic effects of diphosphonate in primary hyperparathyroidism. In: Journal of Clinical Pharmacology. 1977 ; Vol. 17, No. 7. pp. 410-419.
@article{71f590d4816a402a9010f21a5caa9446,
title = "Metabolic effects of diphosphonate in primary hyperparathyroidism",
abstract = "Six patients with primary hyperparathyroidism (PHPT) and one with squamous cell carcinoma of the esophagus with parathyroid hormone excess received disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) at a daily dose of 20 mg/kg orally. During treatment, the decrease in urinary calcium, total urinary hydroxyproline, and fasting urinary calcium suggested an inhibition of bone resorption. Serum calcium intestinal absorption of calcium and urinary cyclic adenosine monophosphate (cAMP) did not change significantly. This preliminary study indicates a possible role of diphosphonates in the management of inoperable cases of primary hyperparathyroidism or pseudohyperparathyroidism.",
author = "Kaplan, {R. A.} and Geho, {W. B.} and C. Poindexter and M. Haussler and Dietz, {G. W.} and Pak, {C. Y.}",
year = "1977",
language = "English (US)",
volume = "17",
pages = "410--419",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Metabolic effects of diphosphonate in primary hyperparathyroidism

AU - Kaplan, R. A.

AU - Geho, W. B.

AU - Poindexter, C.

AU - Haussler, M.

AU - Dietz, G. W.

AU - Pak, C. Y.

PY - 1977

Y1 - 1977

N2 - Six patients with primary hyperparathyroidism (PHPT) and one with squamous cell carcinoma of the esophagus with parathyroid hormone excess received disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) at a daily dose of 20 mg/kg orally. During treatment, the decrease in urinary calcium, total urinary hydroxyproline, and fasting urinary calcium suggested an inhibition of bone resorption. Serum calcium intestinal absorption of calcium and urinary cyclic adenosine monophosphate (cAMP) did not change significantly. This preliminary study indicates a possible role of diphosphonates in the management of inoperable cases of primary hyperparathyroidism or pseudohyperparathyroidism.

AB - Six patients with primary hyperparathyroidism (PHPT) and one with squamous cell carcinoma of the esophagus with parathyroid hormone excess received disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) at a daily dose of 20 mg/kg orally. During treatment, the decrease in urinary calcium, total urinary hydroxyproline, and fasting urinary calcium suggested an inhibition of bone resorption. Serum calcium intestinal absorption of calcium and urinary cyclic adenosine monophosphate (cAMP) did not change significantly. This preliminary study indicates a possible role of diphosphonates in the management of inoperable cases of primary hyperparathyroidism or pseudohyperparathyroidism.

UR - http://www.scopus.com/inward/record.url?scp=0017701521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017701521&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 410

EP - 419

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -